The patients with tumor displaying the phenotype EGFR+/EGF+ had a significantly impaired OS compared to those with EGFR+/EGF− (48.1% versus 84.2%; p < 0.000; Fisher's exact test) (Table 6). Here, EGFR is linked to neoplasm.